Whanin Pharm (016580) - Total Liabilities

Latest as of September 2025: ₩47.06 Billion KRW ≈ $31.89 Million USD

Based on the latest financial reports, Whanin Pharm (016580) has total liabilities worth ₩47.06 Billion KRW (≈ $31.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Whanin Pharm cash flow conversion to assess how effectively this company generates cash.

Whanin Pharm - Total Liabilities Trend (2009–2024)

This chart illustrates how Whanin Pharm's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Whanin Pharm's assets to evaluate the company's liquid asset resilience ratio.

Whanin Pharm Competitors by Total Liabilities

The table below lists competitors of Whanin Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
GPT Healthcare Ltd NSE:GPTHEALTH	India	Rs2.10 Billion
ADF Group Inc. TO:DRX	Canada	CA$136.46 Million
Mangata Holding S.A. WAR:MGT	Poland	zł343.82 Million
Firefly AB (publ) ST:FIRE	Sweden	Skr118.78 Million
Yiren Digital Ltd F:19YA	Germany	€5.11 Billion
Indomobil Multi Jasa Tbk JK:IMJS	Indonesia	Rp26.66 Trillion
Greenheart Gold Inc. V:GHRT	Canada	CA$2.24 Million
JLK Inc KQ:322510	Korea	₩33.18 Billion

Liability Composition Analysis (2009–2024)

This chart breaks down Whanin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 016580 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.12	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Whanin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Whanin Pharm (2009–2024)

The table below shows the annual total liabilities of Whanin Pharm from 2009 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩48.70 Billion ≈ $33.01 Million	+13.22%
2023-12-31	₩43.02 Billion ≈ $29.15 Million	+21.36%
2022-12-31	₩35.45 Billion ≈ $24.02 Million	-1.44%
2021-12-31	₩35.96 Billion ≈ $24.37 Million	+9.12%
2020-12-31	₩32.96 Billion ≈ $22.33 Million	+8.33%
2019-12-31	₩30.42 Billion ≈ $20.62 Million	+8.26%
2018-12-31	₩28.10 Billion ≈ $19.04 Million	-11.50%
2017-12-31	₩31.75 Billion ≈ $21.52 Million	+36.22%
2016-12-31	₩23.31 Billion ≈ $15.80 Million	+23.35%
2012-12-31	₩18.90 Billion ≈ $12.81 Million	+16.26%
2011-12-31	₩16.25 Billion ≈ $11.02 Million	+54.67%
2009-12-31	₩10.51 Billion ≈ $7.12 Million	--

About Whanin Pharm

KO:016580 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$122.71 Million

₩181.07 Billion KRW

Market Cap Rank

#18415 Global

#929 in Korea

Share Price

₩11860.00

Change (1 day)

+0.68%

52-Week Range

₩10030.00 - ₩13130.00

All Time High

₩24391.10